Dokument: Lacosamide has protective disease modifying properties in experimental vincristine neuropathy
| Titel: | Lacosamide has protective disease modifying properties in experimental vincristine neuropathy | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=28419 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20140219-123510-7 | |||||||
| Kollektion: | Dissertationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Abschlussarbeiten » Dissertation | |||||||
| Medientyp: | Text | |||||||
| Autor: | Dr. rer. nat. Beyreuther, Bettina [Autor] | |||||||
| Dateien: |
| |||||||
| Beitragende: | Prof. Dr. med. Korth, Carsten [Gutachter] Prof. Dr. med. Seitz, Rüdiger J. [Gutachter] | |||||||
| Dewey Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften » 610 Medizin und Gesundheit | |||||||
| Beschreibungen: | vincristine neuropathy
Pain and paresthesias are the most common symptoms of chemotherapy-induced painful neuropathy (CIPN). Current treatment and preventive strategies of CIPN are ineffective, and the neuropathy may lead to discontinuation of anti-tumor therapy. Here experimental vincristine-induced neuropathy in rats was used to evaluate the disease-modifying potential of lacosamide using a sustained release formulation and the acute treatment effects of a rapid release formulation. Pain behavior was assessed by withdrawal responses to von Frey hairs, acetone drops, the Randall-Selitto device, and to radiant heat. Preventive lacosamide treatment (30 mg/kg subcutaneously b.i.d. for 17 days) was well tolerated, and pharmacokinetic analysis revealed a peak plasma concentration 2 hours post-injection with a plasma half-life of approximately 3 hours. Rats treated with lacosamide, in contrast to vehicle-treated rats, did not develop vincristine-induced cold allodynia. A protective disease modifying potency of lacosamide could thus be demonstrated in an animal model of CIPN. Lacosamide may be a promising candidate for preventive treatment of CIPN in patients receiving chemotherapy with vinca alkaloids or platinum drug.vincristine neuropathy Pain and paresthesias are the most common symptoms of chemotherapy-induced painful neuropathy (CIPN). Current treatment and preventive strategies of CIPN are ineffective, and the neuropathy may lead to discontinuation of anti-tumor therapy. Here experimental vincristine-induced neuropathy in rats was used to evaluate the disease-modifying potential of lacosamide using a sustained release formulation and the acute treatment effects of a rapid release formulation. Pain behavior was assessed by withdrawal responses to von Frey hairs, acetone drops, the Randall-Selitto device, and to radiant heat. Preventive lacosamide treatment (30 mg/kg subcutaneously b.i.d. for 17 days) was well tolerated, and pharmacokinetic analysis revealed a peak plasma concentration 2 hours post-injection with a plasma half-life of approximately 3 hours. Rats treated with lacosamide, in contrast to vehicle-treated rats, did not develop vincristine-induced cold allodynia. A protective disease modifying potency of lacosamide could thus be demonstrated in an animal model of CIPN. Lacosamide may be a promising candidate for preventive treatment of CIPN in patients receiving chemotherapy with vinca alkaloids or platinum drug. | |||||||
| Lizenz: |  Urheberrechtsschutz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät » Institute » Institut für Neuropathologie | |||||||
| Dokument erstellt am: | 19.02.2014 | |||||||
| Dateien geändert am: | 19.02.2014 | |||||||
| Promotionsantrag am: | 15.12.2012 | |||||||
| Datum der Promotion: | 10.02.2014 |
